Page last updated: 2024-08-23
paclitaxel and xl147
paclitaxel has been researched along with xl147 in 2 studies
Research
Studies (2)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Burris, H; Campana, F; Ciruelos, E; Garcia, AA; Gartner, E; Jiang, J; Krop, I; Maurer, M; Mayer, IA; Saura, C; Tolaney, S; Winer, E; Wu, B; Xu, Y | 1 |
| Castell, C; Jiang, J; Lager, J; Liu, L; Mutch, D; Traynor, AM; Wheler, J | 1 |
Trials
2 trial(s) available for paclitaxel and xl147
| Article | Year |
|---|---|
Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Phosphoinositide-3 Kinase Inhibitors; Quinoxalines; Receptor, ErbB-2; Sulfonamides; Trastuzumab | 2015 |
Phase I Dose-Escalation Study of Pilaralisib (SAR245408, XL147) in Combination with Paclitaxel and Carboplatin in Patients with Solid Tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinoxalines; Sulfonamides | 2017 |